$TWST earnings report

Record fiscal 2026 revenue of $459.4 million, up 22%; fourth-quarter revenue of $126.6 million, up 28%; fiscal 2027 revenue guidance of $550M to $560M. AlphAI read Twist Bioscience's Q4 FY2026 and FY2026 (full year) filing as solid. 2 quarters are on record below.

Q4 FY2026 and FY2026 (full year)

AlphAI · Earnings readTWST · Q4 FY2026 and FY2026 (full year) · ended 2026-09-30

Record fiscal 2026 revenue of $459.4 million, up 22%; fourth-quarter revenue of $126.6 million, up 28%; fiscal 2027 revenue guidance of $550M to $560M

✓Solid quarter

Revenue grew 22% for the full year and 28% in the fourth quarter, gross margin rose to 52.4% for the year, and adjusted EBITDA was positive in the fourth quarter at $2.2 million. The company still reported a full-year GAAP net loss of $130.2 million, and the release gives no quarter-on-quarter total revenue figure.

Revenue
$459M
22% y/y
DSPS (DNA Synthesis and Protein Solutions), fiscal 2026 (twelve months)
$222M
31.7% y/y
Gross margin · GAAP
52.4%
+1.7 margin points y/y
EPS · GAAP
$(2.08)
FY2027 (full fiscal year) outlook
approximately $550 million to $560 million, growth of approximately 21% year over year at the midpoint
GM approximately 52.5% to 53%

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenues, fiscal 2026 (twelve months ended Sep 30, 2026)GAAP$459.4M–22%
Total revenues, Q4 FY2026 (three months ended Sep 30, 2026)GAAP$126.6M–28%
DSPS revenue, fiscal 2026 (twelve months)GAAP$221.9M–31.7%
NGS Applications revenue, fiscal 2026 (twelve months)GAAP$237.5M–14.1%
DSPS revenue, Q4 FY2026 (three months)GAAP$61M8%33%
NGS Applications revenue, Q4 FY2026 (three months)GAAP$65.7M6%24%
Cost of revenues, fiscal 2026 (twelve months)GAAP$218.6M––
Cost of revenues, Q4 FY2026 (three months)GAAP$59.4M––
Gross margin, fiscal 2026 (twelve months)GAAP52.4%–+1.7 margin points
Gross margin, Q4 FY2026 (three months)GAAP53.1%––
Research and development expenses, fiscal 2026 (twelve months)GAAP$71.8M––
Research and development expenses, Q4 FY2026 (three months)GAAP$17M––
Selling, general and administrative expenses, fiscal 2026 (twelve months)GAAP$301.2M––
Selling, general and administrative expenses, Q4 FY2026 (three months)GAAP$74.7M––
Litigation settlement costs, net of recoveries, fiscal 2026 (twelve months, as printed in statement of operations)GAAP$7.21M––
Loss from operations, fiscal 2026 (twelve months, as printed in thousands)GAAP−$139.5M––
Loss from operations, Q4 FY2026 (three months, as printed in thousands)GAAP−$24.41M––
Gain on sale of business, fiscal 2026 (twelve months; prior-year column is fiscal 2025)GAAP—––
Interest income, fiscal 2026 (twelve months)GAAP$8.80M––
Interest income, Q4 FY2026 (three months)GAAP$3.42M––
Income tax expense line as printed, fiscal 2026 (twelve months)GAAP−406K––
Income tax expense line as printed, Q4 FY2026 (three months)GAAP201K––
Net loss, fiscal 2026 (twelve months)GAAP$130.2M––
Net loss, Q4 FY2026 (three months)GAAP$20.6M––
Net loss per diluted share, fiscal 2026 (twelve months)GAAP$(2.08)––
Net loss per diluted share, Q4 FY2026 (three months)GAAP$(0.32)––
Adjusted EBITDA, fiscal 2026 (twelve months)non-GAAP−$35.9M––
Adjusted EBITDA, Q4 FY2026 (three months)non-GAAP$2.2M––
Cash, cash equivalents and short-term investments, as of Sep 30, 2026otherapproximately $582 million––
Total assets, as of Sep 30, 2026GAAP$1.12B––
Total liabilities, as of Sep 30, 2026GAAP$233.8M––
Total stockholders' equity, as of Sep 30, 2026GAAP$888.0M––
Customers shipped to, fiscal 2026 (approximately)otherapproximately 4,100 customers––
Genes physically shipped, fiscal 2026 (approximately)otherapproximately 1.3 million genes––

Segments

SegmentRevenueq/qy/y
DSPS (DNA Synthesis and Protein Solutions), fiscal 2026 (twelve months)The release does not state a driver for this segment's revenue change.$221.9M–31.7%
NGS Applications, fiscal 2026 (twelve months)The release does not state a driver for this segment's revenue change.$237.5M–14.1%
DSPS (DNA Synthesis and Protein Solutions), Q4 FY2026 (three months)The release does not state a driver for this segment's revenue change.$61M8%33%
NGS Applications, Q4 FY2026 (three months)The release does not state a driver for this segment's revenue change.$65.7M6%24%

FY2027 (full fiscal year) outlook

  • Revenueapproximately $550 million to $560 million, growth of approximately 21% year over year at the midpoint
  • Gross marginapproximately 52.5% to 53%
  • NoteAdjusted EBITDA positive
  • NoteCapital expenditures of approximately $75 million as part of our two-year investment plan, excluding landlord-funded tenant improvements
  • NoteInitial full year revenue guidance assumes $100 million in revenue for AI drug discovery and sequential growth across both DNA Synthesis and Protein Solutions and NGS Applications
  • NoteQ1 FY2027 total revenue of approximately $130 million to $132 million, growth of approximately 26% year over year at the midpoint and continued sequential growth

Capital returns

  • The release reports no share repurchases or dividends for fiscal 2026.
  • The company raised net proceeds of approximately $425 million through an equity offering and at-the-market sales (listed under Recent Highlights; period not further specified).

What drove it

  • The CEO attributes the top-line growth to strong demand and states that AI and personalized medicine are increasing demand for customization at scale; this is management's explanation.
  • Management states that the company is investing in capacity, automation and new products, and that fiscal 2027 guidance includes $100 million of revenue for AI drug discovery.
  • Customers shipped to rose to approximately 4,100 in fiscal 2026 from approximately 3,800 in fiscal 2025, and genes physically shipped rose to approximately 1.3 million from approximately 938,000.
  • The release states that gross margin improved 1.7 margin points for fiscal 2026. The release does not state the cause of this change.
  • Management reports a 15th consecutive quarter of sequential growth in revenue.
  • The release lists new products and partnerships: Lilly TuneLab antibody characterization services, Twist Express Screening Antibodies, and Twist MRD Express.

Concerns

  • Full-year GAAP net loss of $130.2 million ($2.08 per diluted share) compared with $77.7 million ($1.30) in fiscal 2025.
  • Selling, general and administrative expenses rose to $301.2 million from $247.0 million for fiscal 2026, while the release describes R&D as decreasing to $71.8 million from $80.3 million.
  • Full-year loss from operations widened to $(139,455) thousand from $(136,259) thousand, and the prior year included a $48,847 thousand gain on sale of business.
  • Fiscal 2027 guidance assumes $75 million of capital expenditures and a $100 million contribution from AI drug discovery; the release notes that demand from AI-enabled drug discovery customers may not continue at current rates.
  • The forward-looking statements section lists dependence on one supplier for a critical component, changes in U.S. trade policies, and the ability to expand manufacturing capacity as risks.
  • The release provides no quarter-on-quarter total revenue figure and no operating cash flow figure.

What to watch

  • Delivery against fiscal 2027 revenue guidance of $550M to $560M and first quarter fiscal 2027 revenue guidance of $130M to $132M.
  • Gross margin against the fiscal 2027 range of approximately 52.5% to 53%.
  • Whether adjusted EBITDA stays positive, as guided for fiscal 2027.
  • Execution of the approximately $75 million capital expenditure plan and the capacity expansion it supports.
  • Whether the AI drug discovery contribution assumed in guidance ($100 million) materializes.
  • The Form 10-K, which the release says is expected to be filed on November 16, 2026.

Balance sheet and cash flow

  • Cash, cash equivalents and short-term investments were approximately $582 million as of September 30, 2026.
  • Balance sheet at September 30, 2026: cash and cash equivalents $533,992 thousand (September 30, 2025: $183,049 thousand); short-term investments $47,915 thousand (2025: $49,385 thousand); inventories $46,411 thousand (2025: $28,309 thousand); property and equipment, net $122,323 thousand (2025: $102,283 thousand).
  • Liability related to the sale of future revenue: $15,000 thousand at September 30, 2026 and $15,000 thousand at September 30, 2025.
  • Operating lease liability, net of current portion: $86,537 thousand (2026) versus $61,750 thousand (2025).
  • Operating cash flow and free cash flow are not presented in the release.

Analysis

Twist reported record full-year fiscal 2026 revenue of $459.4 million, up 22% from $376.6 million, and fourth-quarter revenue of $126.6 million, up 28% from $99.0 million. Both reported segments grew on a year-over-year basis: DSPS rose 31.7% to $221.9 million for the year and 33% to $61.0 million in the quarter, while NGS Applications rose 14.1% to $237.5 million for the year and 24% to $65.7 million in the quarter. In the fourth quarter, DSPS grew 8% and NGS grew 6% sequentially. The release does not give a driver for either segment's change beyond management's general comments on AI-enabled discovery and personalized medicine.

Gross margin was 52.4% for fiscal 2026, against 50.7% a year earlier, an improvement the release describes as 1.7 margin points. Fourth-quarter gross margin was 53.1% against 51.3% in the same quarter of fiscal 2025. Cost of revenues rose to $218.6 million for the year and $59.4 million for the quarter. Operating expenses moved differently: R&D fell to $71.8 million from $80.3 million for the year, while selling, general and administrative expenses rose to $301.2 million from $247.0 million. Fourth-quarter R&D was flat at $17.0 million and SG&A rose to $74.7 million from $63.8 million. The release also reports a $7,205 thousand litigation settlement cost in fiscal 2026.

Profitability is still negative on a GAAP basis. The full-year net loss was $130.2 million, or $2.08 per diluted share, compared with $77.7 million, or $1.30, in fiscal 2025. The fourth-quarter net loss narrowed to $20.6 million, or $0.32 per diluted share, from $27.1 million, or $0.45. Adjusted EBITDA, a non-GAAP measure, was $(35.9) million for the year against $(46.9) million, and $2.2 million in the fourth quarter against $(7.8) million. Interest income fell to $8,803 thousand for the year from $11,364 thousand, and the prior-year column includes a $48,847 thousand gain on sale of business that does not recur in fiscal 2026.

The balance sheet expanded. Management reports net proceeds of approximately $425 million from an equity offering and at-the-market sales, and cash, cash equivalents and short-term investments were approximately $582 million at September 30, 2026. Total assets rose to $1,121,808 thousand from $641,861 thousand and stockholders' equity to $888,016 thousand from $472,958 thousand. The release does not present operating or free cash flow.

Fiscal 2027 guidance calls for revenue of approximately $550 million to $560 million, about 21% growth at the midpoint, gross margin of approximately 52.5% to 53%, positive adjusted EBITDA, and capital expenditures of approximately $75 million excluding landlord-funded tenant improvements. The guidance includes $100 million of revenue for AI drug discovery. First-quarter fiscal 2027 revenue is guided to $130 million to $132 million, about 26% growth at the midpoint. No prior outlook was supplied, so the guidance cannot be compared with earlier expectations.

Management, verbatim

Fiscal 2026 demonstrated what Twist can deliver: strong top line revenue growth, expanded gross margin and positive adjusted EBITDA in the fourth quarter, all while continuing to broaden our capabilities and strengthen our balance sheet,

Emily M. Leproust, Ph.D., CEO and co-founder

AI is expanding what scientists can design, and personalized medicine is increasing the demand for unique molecules.

Emily M. Leproust, Ph.D., CEO and co-founder

Not in the filing

stated, not guessed
  • Quarter-on-quarter change and prior-quarter (Q3 FY2026) total revenue, total gross margin, operating expenses, net loss and EPS are not printed.
  • Year-over-year percentage changes for cost of revenues, gross margin in the quarter, R&D, SG&A, operating loss, net loss, EPS and adjusted EBITDA are not printed.
  • Prior-year cash, cash equivalents and short-term investments combined figure is not printed.
  • Operating cash flow, free cash flow, share repurchases and dividends (none reported) are not printed.
  • Operating expense guidance and tax rate guidance for fiscal 2027 are not printed.
  • Prior outlook for fiscal 2026 was not provided, so vs_prior_guidance is empty.
  • Segment drivers for DSPS and NGS Applications are not stated in the release.
  • Consensus estimates and share price reaction are not provided in the documents.
  • Sign convention of the income tax expense line is printed without a clear sign in the statement of operations; values are copied as printed.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

third quarter of fiscal 2026

AlphAI · Earnings readTWST · third quarter of fiscal 2026 · ended June 30, 2026

Record revenue of $118.4 million in 3QFY26; FY 2026 Revenue guidance raised to $456-$457M; Reiterating Q4 FY26 Adj EBITDA breakeven

✓Solid quarter

Revenue grew 23% to a record $118.4 million, both operating segments delivered sequential growth, gross margin expanded sequentially, and full-year revenue guidance was raised. The result remains weighed by a $35.1 million net loss and adjusted EBITDA of $(11.3) million.

Revenue
$118M
23% y/y
DNA Synthesis and Protein Solutions (DSPS)
$56.6M
39% y/y · 6% q/q
Gross margin · GAAP
52.8%
120 basis points q/q
EPS · GAAP
$0.56
fiscal 2026 and fourth quarter of fiscal 2026 outlook
For the full fiscal year 2026, total revenue in the range of $456 million to $457 million, growth of approximately 21% year over year. For the fourth quarter, total revenue of approximately $123 million to $124 million, growth of approximately 25% year over year at the midpoint.
GM For the full fiscal year 2026, gross margin to be above 52%.

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenuesGAAP$118.4M–23%
Cost of revenuesGAAP$55.9M––
Gross marginGAAP52.8%120 basis points–
Research and development expensesGAAP$18M––
Selling, general and administrative expensesGAAP$80.7M––
Net (loss) incomeGAAP−$35.1M––
Net (loss) income per diluted shareGAAP$0.56 per diluted share––
Adjusted EBITDAnon-GAAP−$11.3M––
Customers shipped products tootherapproximately 2,650 customers––
Genes physically shippedotherapproximately 369,000 genes––

Segments

SegmentRevenueq/qy/y
DNA Synthesis and Protein Solutions (DSPS)Revenue grew compared to $40.8 million for the same period of fiscal 2025 and compared to $53.3 million for the second quarter of fiscal 2026.$56.6M6%39%
NGS Applications (NGS)Revenue grew compared to $55.3 million for the same period of fiscal 2025 and compared to $57.4 million for the second quarter of fiscal 2026.$61.8M8%12%

fiscal 2026 and fourth quarter of fiscal 2026 outlook

  • RevenueFor the full fiscal year 2026, total revenue in the range of $456 million to $457 million, growth of approximately 21% year over year. For the fourth quarter, total revenue of approximately $123 million to $124 million, growth of approximately 25% year over year at the midpoint.
  • Gross marginFor the full fiscal year 2026, gross margin to be above 52%.
  • NoteFor the fourth quarter, sequential growth in both DSPS and NGS Applications.
  • NoteFor the fourth quarter, achieve adjusted EBITDA breakeven.

What drove it

  • Twist reported its fourteenth consecutive quarter of growth.
  • DSPS revenue grew 39% year over year and 6% sequentially.
  • NGS revenue grew 12% year over year and 8% sequentially.
  • Gross margin was 52.8%, up sequentially from 51.6% in the second quarter of fiscal 2026.
  • The company launched Twist Complex Genes commercially for broad access following an early access period.
  • The company reported consecutive quarter over quarter growth in genes manufactured for data characterization.

Concerns

  • Net loss was $(35.1) million, compared to net income of $20.4 million for the same period of fiscal 2025.
  • The third quarter of fiscal 2025 included a gain of $48.8 million from the spin out of Atlas Data Storage.
  • Adjusted EBITDA was $(11.3) million, compared to $(8.0) million for the same period of fiscal 2025.
  • Selling, general and administrative expenses were $80.7 million, compared to $63.4 million for the same period of fiscal 2025.
  • The company continues to target adjusted EBITDA breakeven rather than providing fourth-quarter GAAP net (loss) income guidance.

What to watch

  • Achievement of adjusted EBITDA breakeven in the fourth quarter of fiscal 2026.
  • Delivery of fourth-quarter total revenue of approximately $123 million to $124 million.
  • Sequential growth in both DSPS and NGS Applications in the fourth quarter.
  • Full-year gross margin above 52%.
  • Whether the company sustains growth in customer shipments and genes physically shipped.

Balance sheet and cash flow

  • As of June 30, 2026, the company had approximately $167 million in cash, cash equivalents and short-term investments.

Analysis

Twist delivered record third-quarter revenue of $118.4 million, up 23% from $96.1 million in the same period of fiscal 2025. The company described this as its fourteenth consecutive quarter of growth. Both segments grew year over year and sequentially: DSPS revenue rose 39% to $56.6 million, while NGS revenue rose 12% to $61.8 million. Customer activity also expanded, with products shipped to approximately 2,650 customers and approximately 369,000 genes physically shipped.

The revenue mix showed faster expansion in DSPS, while NGS remained the larger reported segment by revenue. Gross margin reached 52.8%, up from 51.6% in the second quarter of fiscal 2026, a sequential improvement of 120 basis points. Cost of revenues increased to $55.9 million from $44.8 million, while research and development expenses remained $18.0 million.

Profitability remains the key counterweight to the revenue and gross-margin progress. Selling, general and administrative expenses increased to $80.7 million from $63.4 million. Net loss was $(35.1) million, or $0.56 per diluted share, versus net income of $20.4 million, or $0.33 per diluted share, in the prior-year period. The company noted that the prior-year quarter included a $48.8 million gain from the spin out of Atlas Data Storage. Adjusted EBITDA was $(11.3) million versus $(8.0) million in the same period of fiscal 2025.

Management raised full-year fiscal 2026 revenue guidance to $456 million to $457 million from prior guidance of $442 to $447 million and continues to expect growth of approximately 21% year over year. It expects fourth-quarter revenue of approximately $123 million to $124 million, sequential growth in both DSPS and NGS Applications, and adjusted EBITDA breakeven. The company also expects full-year gross margin to be above 52%. Cash, cash equivalents and short-term investments were approximately $167 million as of June 30, 2026.

Management, verbatim

We continued our pattern of strong growth, reporting our fourteenth consecutive quarter of growth and exceeding guidance with revenue for the third quarter of fiscal 2026 of $118.4 million, growth of more than 23% compared to the third quarter of fiscal 2025.

Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience

Well into our final quarter of the fiscal year, we remain confident in our trajectory and continue to expect to achieve adjusted EBITDA breakeven this quarter. That milestone is not the destination. It's the foundation for delivering disciplined execution and profitable growth as we move through fiscal 2027.

Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience

Not in the filing

stated, not guessed
  • Operating income or loss was not reported in the provided document.
  • Gross profit was not reported in the provided document.
  • Prior-year gross margin was not reported.
  • Prior-quarter total revenue was not reported.
  • Prior-quarter cost of revenues, research and development expenses, selling, general and administrative expenses, net (loss) income, diluted EPS, and adjusted EBITDA were not reported.
  • Operating cash flow was not reported.
  • Free cash flow was not reported.
  • Capital expenditures were not reported.
  • Debt was not reported.
  • Share repurchases were not reported.
  • Dividends were not reported.
  • Tax rate was not reported.
  • A separate previous outlook document was not provided for a formal vs_prior_guidance comparison.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about TWST earnings dates

When is Twist Bioscience's next earnings date?
AlphAI has no date for TWST yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.